Breaking News

Juniper, Crystec Ink Deal for Next Gen Medicines

February 16, 2016

Will collaborate as part of the UK-based consortium AMSCI

Juniper Pharma Services has teamed up with CrystecPharma on a major multi-partner project as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI) to help create a new platform to accelerate drug development in the future.

Both companies will collaborate as part of this UK-based consortium of partners that includes two of the world’s biggest pharmaceutical companies. The program aims to develop and demonstrate the capability of supercritical fluid technology in manufacturing smarter, higher quality pharmaceutical products, while moving products more quickly from research to the marketplace.

In just three years, AMSCI is expecting the joint platform to create products from concept to manufacture.

CrystecPharma designs crystals and particles aimed at meeting targeted performance requirements of a medicine. Juniper Pharma Services will bring its expertise in characterization, formulation development and GMP production to the supercritical fluid manufacturing platform.

“Working with CrystecPharma in collaboration with the other AMSCI partners is very exciting, as this alliance will produce a real step change in the advanced manufacturing of next-generation medicines,” said Nikin Patel, president, Juniper Pharma Services.

As a result of the project, CrystecPharma will refocus its manufacturing capability from China to the UK, working with Juniper Pharma Services as its international contract development and manufacturing organization (CDMO) partner. The technology company aims to develop three new products through this program.

“Such a collaborative campaign has the potential to really demonstrate the global competitiveness of the UK in pharmaceutical technology development and manufacturing,” said Paul Thorning, chief executive officer, CrystecPharma. “It will benefit from the invaluable expertise of the team at Juniper, which will enable our novel technology to move into a GMP compliant environment. Working closely with Juniper in this way allows us to rapidly establish the manufacturing capabilities needed to see us through to clinical trials.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research